

01-11-01

A

01/09/01
JC984 U.S. P.O.
Fish P. Fish
1855-1930

FISH RICHARDSON P.C.

4350 La Jolla Village Drive
Suite 500
San Diego, California
92122

Telephone
858 678-5070

Facsimile
858 678-5099

Web Site
www.fr.com

1c841 U.S. PTO
09/757774
01/09/01

W.K. Richardson
1859-1951

January 9, 2001

Attorney Docket No.: 07265-124005

Box Patent Application
Commissioner for Patents
Washington, DC 20231

Presented for filing is a new continuation patent application of:

Applicant: HOWARD DINTZIS and RENEE Z. DINTZIS

Title: THERAPEUTIC SUPPRESSION OF SPECIFIC IMMUNE
RESPONSES BY ADMINISTRATION OF OLIGOMERIC FORMS OF
ANTIGEN OF CONTROLLED CHEMISTRY

The prior application is assigned of record to Johns Hopkins University,
a Maryland corporation, by virtue of an assignment submitted to the Patent and
Trademark Office and recorded on February 18, 1992 at 6028/0944-51.

Enclosed are the following papers, including those required to receive a filing date
under 37 CFR §1.53(b):

	<u>Pages</u>
Specification	144
Claims	9
Abstract	1
Declaration	Unsigned
Drawing(s)	52



BOSTON

DALLAS

DELAWARE

NEW YORK

SAN DIEGO

SILICON VALLEY

TWIN CITIES

WASHINGTON, DC

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EL558601890US

I hereby certify under 37 CFR §1.10 that this correspondence is being
deposited with the United States Postal Service as Express Mail Post
Office to Addressee with sufficient postage on the date indicated below
and is addressed to the Commissioner for Patents, Washington,
D.C. 20231.

Date of Deposit January 9, 2001

Signature

Richard Donovan

Typed or Printed Name of Person Signing Certificate

Commissioner for Patents
January 8, 2001
Page 2



Enclosures:

- Copy of Parent Application with drawing;
- Form PTO-1449, 3 pages, listing documents cited in the parent application(s). Please confirm that these have been considered in this application by returning a copy of the Form PTO-1449 with the examiner's initials.
- Preliminary amendment, 11 pages.
- Petition to Correct Inventorship, 2 pages.
- Response to Notice to Comply With Sequence Rules/Request For Transfer of Sequence Information, 9 pages.
- Postcard.

--This application is a continuation of (and claims the benefit of priority under 35 USC 120) of U.S. Patent Applications Serial No. ("USSN") 08/440,331, filed May 12, 1995, now pending and USSN 08/440,322, filed May 12, 1995, now pending, which are continuations of USSN 08/391,267, filed February 21, 1995, issued as U.S. Patent No. 6,022,544, on February 8, 2000, which is a continuation of USSN 07/808,797, filed Dec. 17, 1991 (now abandoned) which is a continuation-in-part of USSN 07/628,858, filed Dec. 17, 1990 (now abandoned), which is a continuation-in-part of USSN 07/354,710, filed May 22, 1989 (now abandoned), which is a continuation-in-part of USSN 07/248,293, filed Sep. 21, 1988, issued as U.S. Patent No. 5,126,131, on June 30, 1992, which is a continuation of USSN 06/869,808, filed May 29, 1986 (now abandoned), which is a continuation of USSN 06/460,266, filed Jan. 24, 1983 (now abandoned). The disclosure of the prior application is considered part of (and is incorporated by reference in) the disclosure of this application.

This application is entitled to small entity status.

Basic filing fee	\$355
Total claims in excess of 20 times \$9	\$216
Independent claims in excess of 3 times \$40	\$40
Fee for multiple dependent claims	\$0
Fee for Petition to Correct Inventorship	\$130
Total filing fee:	\$741

A check for the filing fee is enclosed. Please apply any other required fees or any credits to deposit account 06-1050, referencing the attorney docket number shown above.

FISH & HARDSON P.C.

FISH & RICHARDSON P.C.

Commissioner for Patents

January 8, 2001

Page 3


If this application is found to be incomplete, or if a telephone conference would otherwise be helpful, please call the undersigned at (858) 678-5070.

Kindly acknowledge receipt of this application by returning the enclosed postcard.

Please send all correspondence to:

GREGORY P. EINHORN
Fish & Richardson P.C.
4350 La Jolla Village Drive, Suite 500
San Diego, CA 92122

Respectfully submitted,


A handwritten signature in black ink, appearing to read "G. P. Einhorn", written over the printed name.

Gregory P. Einhorn

Reg. No. 38,440

Enclosures

GPE/mzc
10066174.doc



W.K. Richardson
1859-1951

FISH RICHARDSON P.C.



January 9, 2001

Attorney Docket No.: 07265-124005

Box Patent Application
Commissioner for Patents
Washington, DC 20231

Presented for filing is a new continuation patent application of:

Applicant: HOWARD DINTZIS and RENEE Z. DINTZIS

Title: THERAPEUTIC SUPPRESSION OF SPECIFIC IMMUNE
RESPONSES BY ADMINISTRATION OF OLIGOMERIC FORMS OF
ANTIGEN OF CONTROLLED CHEMISTRY

The prior application is assigned of record to Johns Hopkins University,
a Maryland corporation, by virtue of an assignment submitted to the Patent and
Trademark Office and recorded on February 18, 1992 at 6028/0944-51.

Enclosed are the following papers, including those required to receive a filing date
under 37 CFR §1.53(b):

	<u>Pages</u>
Specification	144
Claims	9
Abstract	1
Declaration	Unsigned
Drawing(s)	52

09/757,774
1-9-01

parent #?
This is not a
request for transfer
M. Spencer

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EL558601890US

I hereby certify under 37 CFR §1.10 that this correspondence is being
deposited with the United States Postal Service as Express Mail Post
Office to Addressee with sufficient postage on the date indicated below
and is addressed to the Commissioner for Patents, Washington,
D.C. 20231.

Date of Deposit January 9, 2001

Signature

Richard Donovan

Typed or Printed Name of Person Signing Certificate

0450
03-13-01
4350 La Jolla Village Drive
Suite 500
San Diego, California
92122
Telephone
858 678-5070
Facsimile
858 678-5099

Web Site
www.fr.com



BOSTON

DALLAS

DELAWARE

NEW YORK

SAN DIEGO

SILICON VALLEY

TWIN CITIES

WASHINGTON, DC

Support for the Claim Amendment

The specification sets forth an extensive description of the invention in the new claims. Support for new claims directed to methods of making a non-immunogenic construct comprising at least two copies of an epitope of a T-dependent antigen bound to a non-immunogenic carrier, wherein the non-immunogenic soluble carrier has been subjected to a preparative sizing technique to remove substantially most high molecular weight non-immunogenic soluble carrier molecules before conjugation, or coupling, to two or more of the epitope molecules, is found, *inter alia*, at page 31, line 39 to page 32, line 9. Support for new claims directed to methods of making a non-immunogenic construct comprising at least two copies of an epitope of a T-dependent antigen bound to a non-immunogenic carrier, wherein soluble carrier has been subjected to a preparative sizing technique to remove substantially most high molecular weight immunogenic soluble carrier molecules after conjugation, or coupling, to two or more of the epitope molecules, is found, *inter alia*, at page 31, line 39 to page 32, line 9.

IDS and FORM PTO 1449

A copy of the Information Disclosure Statement and FORM PTO 1449 filed with the parent application is enclosed herewith.

Sequence Listing as required by 37 CFR §§1.821(c), 1.822 and 1.823

The application has been amended to insert SEQ ID NO:'s into the specification of the application. A RESPONSE TO NOTICE TO COMPLY WITH SEQUENCE RULES/ REQUEST FOR TRANSFER OF SEQUENCE INFORMATION is filed herewith.

Petition to Correct Inventorship under 37 CFR §1.48(b)

James K. Blodgett, John C. Cheronis, and Gary Kirschenheuter have been deleted as co-inventors; these individuals were co-inventors solely on claims pertaining to chemically-derivitized suppressing constructs (originally filed claims 20-23, 25, 33, 36, and 39-43) which, after entry of the instant amendment, will be no longer pending in the present application. A Petition to Correct Inventorship under 37 CFR §1.48(b) is being filed with this amendment.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Dintzis et al.
 Serial No. : 08/440,322
 Filed : May 12, 1995
 Title : THERAPEUTIC SUPPRESSION OF SPECIFIC IMMUNE RESPONSES BY
 ADMINISTRATION OF OLIGOMERIC FORMS OF ANTIGEN OF
 CONTROLLED CHEMISTRY

Art Unit : 1644
 Examiner : D. Saunders

Assistant Commissioner for Patents
 Washington, D.C. 20231

jc841 U.S. PTO
 09/757774
 01/09/01

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE AND/OR AMINO ACID SEQUENCES

In response to the communication dated November 24, 1999, applicant submits herewith a Sequence Listing in computer readable form as required by 37 CFR §1.824. In addition, applicant submits a Sequence Listing as required under 37 CFR §1.823(a) and a statement under 37 CFR §1.821(f).

I hereby state that this submission, filed in accordance with 37 CFR §1.821(g), does not contain new matter.

Respectfully submitted,

Date: 3/24/00

IA Beattie
 Ingrid A. Beattie, Ph.D., J.D.
 Reg. No. 42,306

Fish & Richardson P.C.
 225 Franklin Street
 Boston, MA 02110-2804
 Telephone: (617) 542-5070
 Facsimile: (617) 542-8906
 20042470.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

March 24, 2000
 Date of Deposit
Darlene J. Morin
 Signature

Darlene J. Morin
 Typed or Printed Name of Person Signing Certificate